154 related articles for article (PubMed ID: 32048382)
41. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
Afify AM; Stern R; Michael CW
Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
[TBL] [Abstract][Full Text] [Related]
42. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
Hwang HC; Sheffield BS; Rodriguez S; Thompson K; Tse CH; Gown AM; Churg A
Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
[TBL] [Abstract][Full Text] [Related]
43. Distinction between cells in serous effusions using a panel of antibodies.
Lauritzen AF
Virchows Arch A Pathol Anat Histopathol; 1987; 411(3):299-304. PubMed ID: 2441518
[TBL] [Abstract][Full Text] [Related]
44. Pleural fluid cytological yield and visceral pleural invasion in patients with epithelioid malignant pleural mesothelioma.
Pinelli V; Laroumagne S; Sakr L; Marchetti GP; Tassi GF; Astoul P
J Thorac Oncol; 2012 Mar; 7(3):595-8. PubMed ID: 22307010
[TBL] [Abstract][Full Text] [Related]
45. Application of the International System for Reporting Serous Fluid Cytopathology (ISRSFC) on Reporting Pericardial Effusion Cytology.
Rodriguez EF; Jones R; Gabrielson M; Santos D; Pastorello RG; Maleki Z
Acta Cytol; 2020; 64(5):477-485. PubMed ID: 32422631
[TBL] [Abstract][Full Text] [Related]
46. Distinguishing benign from malignant mesothelial cells in effusions by Glut-1, EMA, and Desmin expression: an evidence-based approach.
Kuperman M; Florence RR; Pantanowitz L; Visintainer PF; Cibas ES; Otis CN
Diagn Cytopathol; 2013 Feb; 41(2):131-40. PubMed ID: 23002041
[TBL] [Abstract][Full Text] [Related]
47. [Evaluation of immunohistochemistry staining and cytologic diagnosis by using cell block sections prepared with effusion fluid cytology specimens].
Mao YY; Yang M; Liu DG; Lin MH; Zhang LQ; Chen ZQ
Zhonghua Bing Li Xue Za Zhi; 2009 Aug; 38(8):547-50. PubMed ID: 20021967
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of AgNOR count in distinguishing benign from malignant mesothelial cells in pleural fluids.
Colecchia M; Leopardi O
Pathol Res Pract; 1992 Jun; 188(4-5):541-4. PubMed ID: 1409085
[TBL] [Abstract][Full Text] [Related]
49. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Diagn Cytopathol; 2011 Jun; 39(6):395-401. PubMed ID: 21574259
[TBL] [Abstract][Full Text] [Related]
50. Immunocytochemical staining of serous effusions with the monoclonal antibody Ber-EP4.
De Angelis M; Buley ID; Heryet A; Gray W
Cytopathology; 1992; 3(2):111-7. PubMed ID: 1617160
[TBL] [Abstract][Full Text] [Related]
51. A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit.
Segal A; Sterrett GF; Frost FA; Shilkin KB; Olsen NJ; Musk AW; Nowak AK; Robinson BW; Creaney J
Pathology; 2013 Jan; 45(1):44-8. PubMed ID: 23222247
[TBL] [Abstract][Full Text] [Related]
52. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells.
Davidson B; Nielsen S; Christensen J; Asschenfeldt P; Berner A; Risberg B; Johansen P
Am J Surg Pathol; 2001 Nov; 25(11):1405-12. PubMed ID: 11684957
[TBL] [Abstract][Full Text] [Related]
53. Soluble triggering receptor expressed on myeloid cells-1 for diagnosing empyema.
Bishara J; Goldberg E; Ashkenazi S; Yuhas Y; Samra Z; Saute M; Shaked H
Ann Thorac Surg; 2009 Jan; 87(1):251-4. PubMed ID: 19101307
[TBL] [Abstract][Full Text] [Related]
54. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
Shield PW; Papadimos DJ; Walsh MD
Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
[TBL] [Abstract][Full Text] [Related]
55. An improved flow cytometric assay for detection and discrimination between malignant cells and atypical mesothelial cells, in serous cavity effusions.
Kentrou NA; Tsagarakis NJ; Tzanetou K; Damala M; Papadimitriou KA; Skoumi D; Stratigaki A; Anagnostopoulos NI; Malamou-Lada E; Athanassiadou P; Paterakis G
Cytometry B Clin Cytom; 2011 Sep; 80(5):324-34. PubMed ID: 21695775
[TBL] [Abstract][Full Text] [Related]
56. Immunocytochemical utility of claudin-4 versus those of Ber-EP4 and MOC-31 in effusion cytology.
Oda T; Ogata S; Kawaguchi S; Minabe S; Dokyu M; Takahashi H; Kumazawa F; Shimazaki H; Takano M; Hase K; Ozeki Y; Kanoh S; Nakanishi K
Diagn Cytopathol; 2016 Jun; 44(6):499-504. PubMed ID: 27015745
[TBL] [Abstract][Full Text] [Related]
57. Monoclonal antibody Ber-EP4: its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens.
Maguire B; Whitaker D; Carrello S; Spagnolo D
Diagn Cytopathol; 1994; 10(2):130-4. PubMed ID: 8187591
[TBL] [Abstract][Full Text] [Related]
58. A panel of markers for identification of malignant and non-malignant cells in culture from effusions.
Carneiro FP; Muniz-Junqueira MI; Pittella-Silva F; Carneiro MV; Takano GHS; Vianna LMS; De Andrade LB; De Castro TMML; Peres I; Dos Santos Borges TK; Ferreira VM; Motoyama AB
Oncol Rep; 2017 Dec; 38(6):3538-3544. PubMed ID: 29039588
[TBL] [Abstract][Full Text] [Related]
59. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K
Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210
[TBL] [Abstract][Full Text] [Related]
60. Combination of Biochemical and Cytological Findings for Better Diagnosis in Pleural Effusions.
Elmas H; Biancosino C; Önal B; Schmitt F; Buyucek S; Nordholt G; Sauter G; Welker L
Adv Exp Med Biol; 2022; 1374():51-62. PubMed ID: 35147931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]